Compare BioNTech SE - ADR (BNTX) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? BioNTech SE - ADR trades at $90.35 (market cap $22.86B), while Direxion Daily S&P 500 Bull 3X Shares trades at $275.6. The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | SPXL | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $119.34 | $288.04 |
52-Week Low | $83.89 | $170.20 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
SPXL is trading at $272.66, down 2.34% today, with a bullish technical signal supported by moving averages. The stock faces resistance at $277-$283 while finding support at $270-$264 levels. Recent news highlights ongoing AI-driven market dynamics and earnings season catalysts that could influence S&P 500 performance.
Outlook remains cautiously optimistic with technical strength but requires monitoring of earnings results and market sentiment. Key risks include stretched valuations and potential market volatility during earnings season. The stock's performance remains tied to broader S&P 500 trends and AI sector developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
